These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Therapeutic vaccines for preventing AIDS: their use with HAART. Hoff R; McNamara J Lancet; 1999 May; 353(9166):1723-4. PubMed ID: 10347978 [No Abstract] [Full Text] [Related]
8. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network. Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820 [TBL] [Abstract][Full Text] [Related]
9. India targets local HIV strain in test of AIDS vaccine. Jayaraman KS Nature; 2004 Jan; 427(6971):185. PubMed ID: 14724601 [No Abstract] [Full Text] [Related]
10. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160. Kovacs JA; Vasudevachari MB; Easter M; Davey RT; Falloon J; Polis MA; Metcalf JA; Salzman N; Baseler M; Smith GE J Clin Invest; 1993 Aug; 92(2):919-28. PubMed ID: 7688766 [TBL] [Abstract][Full Text] [Related]
11. HIV-1/AIDS vaccine development: are we in the darkness. Qiu C; Xu JQ Chin Med J (Engl); 2008 May; 121(10):939-45. PubMed ID: 18706210 [No Abstract] [Full Text] [Related]
12. The rational design of an AIDS vaccine. Douek DC; Kwong PD; Nabel GJ Cell; 2006 Feb; 124(4):677-81. PubMed ID: 16497577 [TBL] [Abstract][Full Text] [Related]
13. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159 [TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. Earl PL; Sugiura W; Montefiori DC; Broder CC; Lee SA; Wild C; Lifson J; Moss B J Virol; 2001 Jan; 75(2):645-53. PubMed ID: 11134278 [TBL] [Abstract][Full Text] [Related]
15. Vaccines for control of AIDS--an update. Sharma KB Indian J Pediatr; 1994; 61(5):535-43. PubMed ID: 7744454 [No Abstract] [Full Text] [Related]
16. Measuring vaccine-induced HIV neutralization: report of a workshop. Hanson CV AIDS Res Hum Retroviruses; 1994 Jun; 10(6):645-8. PubMed ID: 8074928 [No Abstract] [Full Text] [Related]
17. [Promising results with the anti-HIV vaccine]. Katlama C Presse Med; 2003 Jun; 32(21):964. PubMed ID: 12876523 [No Abstract] [Full Text] [Related]
18. Protection of monkeys vaccinated with vpr- and/or nef-defective simian immunodeficiency virus strain mac/human immunodeficiency virus type 1 chimeric viruses: a potential candidate live-attenuated human AIDS vaccine. Igarashi T; Ami Y; Yamamoto H; Shibata R; Kuwata T; Mukai R; Shinohara K; Komatsu T; Adachi A; Hayami M J Gen Virol; 1997 May; 78 ( Pt 5)():985-9. PubMed ID: 9152414 [TBL] [Abstract][Full Text] [Related]
20. Hope in a vial. Will there be an AIDS vaccine anytime soon? Ezzell C Sci Am; 2002 Jun; 286(6):38-45. PubMed ID: 12030090 [No Abstract] [Full Text] [Related] [Next] [New Search]